Previous 10 | Next 10 |
Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered into an exclusive development and commercialization agreement for Rhopressa ® and Rocklatan ® in ...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today t...
Gainers: Kaixin Auto (KXIN) +317%.Dragon Victory International (LYL) +107%.Marine Petroleum Trust (MARPS) +62%.BOQI International Medical (BIMI) +59%.Dogness (DOGZ) +45%.Dunxin Financial (DXF) +44%.BioSpecifics Technologies (BSTC) +44%.Front Yard Residential (RESI) +35%.Li...
Gainers: BOQI International Medical (BIMI) +70%, BioSpecifics Technologies (BSTC) +44%, Liquidia Technologies (LQDA) +19%, OraSure Technologies (OSUR) +17%, Centogene (CNTG) +17%.Losers: Aerie Pharmaceuticals (AERI) -14%, ReWalk Robo...
Molina Healthcare announces acquisition of Affinity Health Plan. Concert Pharmaceuticals reports completing recruitment in schizophrenia trial. Aerie Pharmaceuticals moves ahead with Dry Eye treatment candidate AR-15512. For further details see: Molina Acquires Affinity,...
The FDA has signed off on a Phase 2 clinical trial evaluating Aerie Pharmaceuticals' (AERI) eye drop AR-15512 in people with dry eye. The study should launch in Q4.The primary endpoints are the changes from baseline in Ocular Discomfort Score and Anesthetized Schirmer Test 0-35 mm at day 28.A...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced ...
Aerie Pharmaceuticals (AERI) has announced interim 90-day topline data from its six-month Phase 3b (Mercury 3) trial in Europe, comparing Roclanda to Ganfort for intraocular pressure ((IOP)) reduction in patients with open-angle glaucoma or ocular hypertension. Topline dat...
- Roclanda ® Achieves Non-Inferiority to Ganfort ® - - Mercury 3 Performance Exceeds Prior Phase 3 Trials - Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in...
The FDA has approved Aerie Pharmaceuticals' (NASDAQ: AERI ) sterile fill production facility in Athlone, Ireland for production of Rhopressa (netarsudil ophthalmic solution) 0.02% for commercial distribution in the U.S. More news on: Aerie Pharmaceuticals, Inc., Healthcare st...
News, Short Squeeze, Breakout and More Instantly...
Aerie Pharmaceuticals Inc. Company Name:
AERI Stock Symbol:
NASDAQ Market:
Aerie Pharmaceuticals Inc. Website:
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Al...
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceut...
NEW YORK, NY / ACCESSWIRE / October 30, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NA...